Navigation Links
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Date:12/13/2007

CAMBRIDGE, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme(R) (alglucosidase alfa) met its co-primary efficacy endpoints. The study was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients with Pompe disease. Myozyme was first approved in 2006, and the product is now registered in 36 countries.

The randomized, double-blind, placebo-controlled study enrolled 90 patients at eight primary sites in the United States and Europe. Participants received either Myozyme or a placebo every other week for 18 months. The average age of study participants was 44 years. The primary efficacy endpoints of the study sought to determine the effect of Myozyme on functional endurance as measured by the six-minute walk test and to determine the effect of Myozyme on pulmonary function as measured by percent predicted forced vital capacity.

The results showed that, at 18 months, patients treated with Myozyme increased their distance walked in six minutes by an average of approximately 30 meters as compared with the placebo group (P=0.0283; Wilcoxon test). The placebo group did not show any improvement from baseline. The average baseline distance walked in six minutes in both groups was approximately 325 meters.

Percent predicted forced vital capacity in the group of patients treated with Myozyme increased by 1 percent at 18 months. In contrast, it declined by approximately 3 percent in the placebo group (P=0.0026; Wilcoxon test). The average baseline percent predicted forced vital capacity in both groups was approximately 53 percent.

The results for both efficacy endpoints were consistent across various prosp
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Researchers ... to interrogate biology, but such devices can do ... As such, researchers have looked to ... in vitro metabolic engineering to characterize – ... chip. New devices are envisioned to recreate animal ...
(Date:7/30/2014)... 30, 2014 Connecticut Center for Advanced ... in East Hartford, Conn., was awarded a Rural Business ... a project that will determine the feasibility of implementing ... Connecticut. USDA Rural Development provided $53,000 for CCAT under ... second phase of the feasibility study in fiscal year ...
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SoundConnect Organization and Culture is Evolving 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
... or ultracapacitors, differ from regular capacitors that you would ... store substantially higher amounts of charges. They have garnered ... discharge faster than batteries, yet they are still limited ... energy density of batteries. An EC that combines the ...
... March 16, 2012  Tarsa Therapeutics, Inc. today announced ... financing led by new investor Foresite Capital.  James ... Tarsa,s Board of Directors.  Tarsa,s existing venture capital ... Partners—all participated in the new financing round.  ...
Cached Biology Technology:CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Researchers develop graphene supercapacitor holding promise for portable electronics 2Researchers develop graphene supercapacitor holding promise for portable electronics 3Researchers develop graphene supercapacitor holding promise for portable electronics 4Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... for spinal cord injury (SCI), traumatic brain injury (TBI) ... deal has been learned over the past 30 years ... that regulate axon growth, but this large body of ... Prof. Lemmon and his team from University of Miami ... causes, but a consensus is emerging that one contributing ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... project to teach undergraduate students about network analysis, turned ... to analyze a National Basketball Association (NBA) basketball team,s ... discovered it is possible to quantify both a team,s ... in an online November issue of PLOS ONE ...
... research from Georgia Aquarium and Georgia Institute of Technology ... can be used to determine the health status of ... fish species. The study, led by Dr. Alistair Dove, ... an adjunct professor at Georgia Tech, found that the ...
... Robertson (Rob) McClung is not your typical clock-watcher. His ... based on a 24-hour period. Living organisms depend upon ... rotation and the recurring changes it imposes on the ... anticipate the changes and adapt to them by modifying ...
Cached Biology News:Basketball teams offer insights into building strategic networks 2New whale shark study used metabolomics to help understand shark and ray health 2Dartmouth research: The clocks are ticking and the climate is changing 2Dartmouth research: The clocks are ticking and the climate is changing 3Dartmouth research: The clocks are ticking and the climate is changing 4
... Do you need to make your ... transformation efficiency? Take advantage of Lucigen’s unrivalled ... Custom Competent Cell Service offers: ... transformation efficiencies Fast turnaround ...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
... Small Molecule Localization in Early ... Get essential drug compound ... mass spectrometry. Protein Discoverys imaging mass spectrometry ... aligns them with histological images so you ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: